EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements

Rachana Raman, Shristi Debata, Thirupugal Govindarajan, Praveen Kumar iD

Cancer Medicine · 2025-05 · 14 (9)

DOI: 10.1002/cam4.70803 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 02.05.2025. Verfasst von Rachana Raman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Photoceutics and Regeneration Laboratory, Department of Biotechnology, Centre for Microfluidics, Biomarkers, Photoceutics and Sensors (μBioPS), Manip…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Biomarkers, Tumor, Antineoplastic Agents. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple‐negative breast cancer (TNBC) is one of the most heterogeneous and menacing forms of breast cancer, with no sustainable cure available in the current treatment landscape. Its lack of targets makes it highly unresponsive to various treatment modalities, which is why chemotherapy continues to be the primary form of treatment, despite the high rates of patients developing chemoresistance. In recent years, however, there has been significant progress in identifying and understanding the role of several aspects that might contribute to genomic instability and other hallmarks of cancer, including cellular proteins, immune targets, and epigenetic mechanisms, which are desirable as they permit reversibility easier than the often‐adamant genetic changes.

Methods

A literature review was conducted on the role of various TNBC associated biomarkers, their therapeutic applications, and their role in tumorigenesis and tumor maintenance, with a focus on linking both the driving biological mechanisms and emerging treatment options for TNBC.

Conclusions

Shifting the focus of treatment to identify crucial tumor cell subpopulations and associated biomarkers, such as local immune cell populations and cancer stem cells, could potentially solve or simplify decades' worth of problems that are associated with TNBC, bolstering early detection and the evolution of precision medicine and treatment. The techniques that can be used here are epigenetic analysis and RNA sequencing. Biomarkers, such as PD‐L1, survivin, and ABC transporters, are implicated in several crucial processes that maintain tumors, such as cell proliferation, metastasis, immunosuppression, and stemness. Complex treatment options such as, immunotherapy, pathway inhibition, PARP inhibition, virotherapy, and RNA targeting have been considered for TNBC. Phytochemicals are also being considered as a treatment modality for TNBC, as a supplement to chemotherapy and radiation therapy, or as sole treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDrug Resistance, NeoplasmBiomarkers, TumorAntineoplastic AgentsHumansFemaleMolecular Targeted TherapyEpigenesis, Genetic

Stichwörter der Autor:innen

biomarkerscancer stem cellsphytochemicalsplasticitysingle‐cell RNA sequencingtumor microenvironment

Substanzen

Biomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Photoceutics and Regeneration Laboratory, Department of Biotechnology, Centre for Microfluidics, Biomarkers, Photoceutics and Sensors (μBioPS), Manipal Institute of Technology, Manipal Academy of Higher Education, Manip…
  • Innotech Manipal, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.

ORCID-Profile: Praveen Kumar

Zitieren

APA

Raman, R., Debata, S., Govindarajan, T., & Kumar, P. (2025). Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements. Cancer Medicine, 14(9). https://doi.org/10.1002/cam4.70803

Vancouver

Raman R, Debata S, Govindarajan T, Kumar P. Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements. Cancer Medicine. 2025;14(9). doi:10.1002/cam4.70803

BibTeX
@article{Raman2025,
  author = {Raman, Rachana and Debata, Shristi and Govindarajan, Thirupugal and Kumar, Praveen},
  title = {Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {9},
  doi = {10.1002/cam4.70803}
}
Kostenlos starten →